GE Healthcare Release: Use of Mammostrat Bioassay Predicts Early Relapse Risk in ER-Positive Postmenopausal Breast Cancer Patients
6/4/2012 11:27:11 AM
CHICAGO--(BUSINESS WIRE)--GE Healthcare today announced results from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial at the 2012 Annual Meeting of the American Society of Clinical Oncology. Results from this study, presented by John M.S. Bartlett, PhD of the Ontario Institute for Cancer Research demonstrated the ability of Mammostrat to predict distant relapse - free survival and disease- free survival for both exemestane and tamoxifen-exemestane treated estrogen receptor-positive (ER+) patients, irrespective of nodal status and chemotherapy.